Skip to main content
. 2022 Feb 19;27:3. doi: 10.1265/ehpm.21-00254

Table 3.

Correlation of SMARCA2 negative expression with clinicopathological features in 2390 cases with NSCLC.

  Total n (%) Expression of SMARCA2 P-value χ2

Positive n (%) Negative n (%)
Age-years 2390 2168 222    
≤60 1018(42.6) 930(42.9) 88(39.6) 0.349 0.874
>60 1372(57.4) 1238(57.1) 134(60.4)
Gender 2390 2168 222    
Male 1077(45.1) 952(43.9) 125(56.3) 4.076E-04* 12.497
Female 1313(54.9) 1216(56.1) 97(43.7)
Smoking history 2390 2168 222    
Yes 568(23.8) 507(23.4) 61(27.5) 0.173 1.861
No 1822(76.2) 1661(76.6) 161(72.5)
Emphysema/Tuberculosis 2390 2168 222    
Yes 77(3.2) 66(3.0) 11(95.0) 0.125 2.358
No 2313(96.8) 2102(97.0) 211(5.0)
Family history 2390 2168 222    
Yes 295(12.3) 267(12.3) 28(12.6) 0.898 0.016
No 2095(87.7) 1901(87.7) 194(87.4)
Tumor location 2390 2168 222    
Central 160(6.7) 146(6.7) 14(6.3) 0.808 0.059
Peripheral 2230(93.3) 2022(93.3) 208(93.7)
Different lung lobes 2390 2168 222    
Middle lobe 196(8.2) 169(7.8) 27(12.2) 0.024* 5.101
Upper & lower lobe 2194(91.8) 1999(92.2) 195(87.8)
Tumor size 2390 2168 222    
<2 cm 1125(47.1) 1064(49.1) 61(27.5) 8.201E-10* 37.712
≥2 cm 1265(52.9) 1104(50.9) 161(72.5)
T-stage 2390 2168 222    
T1 1627(68.1) 1514(69.8) 113(50.9) 1.465E-10* 48.763
T2 647(27.1) 565(26.1) 82(36.9)
T3 67(2.8) 49(2.3) 18(8.1)
T4 49(2.0) 40(1.8) 9(4.1)
N-stage 2390 2168 222    
N0 2007(84.0) 1849(85.3) 158(71.2) 4.757E-08* 29.814
N+ 383(16.0) 319(14.7) 64(28.8)
M-stage 2390 2168 222    
M0 2371(99.2) 2151(99.2) 220(99.1) 1.000 2.983E-28
M+ 19(0.8) 17(0.8) 2(0.9)
TNM Stage
(UICC/AJCC 8th)
2390 2168 222    
I 1897(79.4) 1758(81.1) 139(62.6) 2.556E-09* 42.923
II 194(8.1) 161(7.4) 33(14.9)
III 280(11.7) 232(10.7) 48(21.6)
IV 19(0.8) 17(0.8) 2(0.9)
Pleural invasion 2390 2168 222    
Yes 523(21.9) 449(20.7) 74(33.3) 1.474E-05* 18.771
No 1867(78.1) 1719(79.3) 148(66.7)
Vascular invasion 2390 2168 222    
Yes 120(5.0) 98(4.5) 22(9.9) 4.612E-04* 12.266
No 2270(95) 2070(95.5) 200(90.1)
STAS 2390 2168 222    
Yes 155(6.5) 141(6.5) 14(6.3) 0.909 0.013
No 2235(93.5) 2027(93.5) 208(93.7)
Necrosis 2390 2168 222    
Yes 228(9.5) 189(8.7) 39(17.6) 1.911E-05* 18.276
No 2162(90.5) 1979(91.3) 183(82.4)
Differentiation states 2386 2164 222    
Well 592(24.8) 577(26.7) 15(6.8) <2.200E-16* 84.030
moderate 923(38.7) 856(39.5) 67(30.2)
Poor 871(36.5) 731(33.8) 140(63.0)
Ki-67 2389 2167 222    
<15% 1177(49.3) 1114(51.4) 63(28.4) 6.294E-11* 42.727
≥15% 1212(50.7) 1053(48.6) 159(71.6)
P53 2388 2166 222    
Aberrant 720(30.2) 632(29.2) 88(39.6) 1.217E-03* 10.464
WT 1668(69.8) 1534(70.8) 134(60.4)
SOX-2 2390 2168 222    
Positive 683(28.6) 638(29.4) 45(20.3) 0.004* 8.274
Negative 1707(71.4) 1530(70.6) 177(79.7)
PD-L1 2386 2164 222    
≤1% 1987(83.3) 1818(84.0) 169(76.1) 0.003* 11.633
1%–50% 186(7.8) 166(7.7) 20(9.0)
≥50% 213(8.9) 180(8.3) 33(14.9)
EGFR 569 504 65    
MT 270(47.5) 237(47.0) 33(50.8) 0.569 0.324
WT 299(52.5) 267(53.0) 32(49.2)
ALK 2390 2168 222    
Positive 40(1.7) 37(1.7) 3(1.4) 0.906 0.014
Negative 2350(98.3) 2131(98.3) 219(98.6)
Classification 2390 2168 222    
AD 2174(91.0) 1969(90.8) 205(92.3) 0.003* 11.777
SCC 200(8.4) 188(8.7) 12(5.4)
Others 16(0.6) 11(0.5) 5(2.3)

Note: *P < 0.05; STAS: spread through air spaces; WT: Wild type; MT: Mutant type.